Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease

NCT03461211 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03461211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03461211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
April 16, 2018
Completion date
February 17, 2021
Enrollment
51 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease